Biogen Inc
NASDAQ: BIIB
$159.99
-$4.90 (-3.0%)
Closing Price on November 15, 2024
BIIB Articles
Billionaire activist investor and financier Carl Icahn has released the total holdings in an SEC filing for the period end December 31, 2007 for ICAHN CAPITAL, LP. As Carl Icahn and his friends are...
Published:
Last Updated:
On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in revenues. Estimates for...
Published:
Last Updated:
Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This data showed that Fampridine, which is designed to...
Published:
Alliance Data Systems (ADS) was informed by Blackstone that conditions likely won’t be satisfied to complete the merger; stock trading down close to 40%.American Express (AXP) reports earnings...
Published:
These are not at all the only key impact analyst calls, but these are the early bird calls that a673b.bigscoots-temp.com is focusing on: Adobe (NASDAQ: ADBE) downgraded to Neutral from Buy at UBS. Biogen Idec...
Published:
Genentech (NYSE: DNA) is set to report earnings after the close today. First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion. This will also mark the end of the fiscal 2007...
Published:
Last Updated:
Below is a snapshot of some of the key impact news affecting stocks in pre-market trading this Monday, January 7, 2008: AllianceBernstein (AB) noted as a hidden gem in Barron’s cover story. Answers...
Published:
There are many other analyst calls today, but these are the main calls we are looking at this morning: Biogen Idec (BIIB) raised from Underperform to Neutral at Credit Suisse. BMC Software (BMC)...
Published:
According to Reuters, Paulson says that China is picking up the pace of the yuan rise. Reuters writesThe Asian Development Bank cut growth rates for countries in Asia including China Reuters reports...
Published:
Biogen-Iden (NASDAQ:BIIB) is seeing its shares pummeled in after-hours trading. The company didn’t have another biotech drug crisis though. Biogen had been under a corporate strategic review...
Published:
Last Updated:
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and...
Published:
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had enjoyed an incredible...
Published:
Last Updated:
Biogen Idec (BIIB) announced an alliance with Neurimmune Therapeutics to develop treatments for Alzheimer’s Disease.BJ’s Wholesale (BJ) $0.35 EPS vs $0.33 est.Blue Coat Systems (BCSI) $0.30 EPS...
Published:
Carl Icahn has done a lot for shared holders at close to a dozen companies over the last year or so. He continues to put pressure on Motorola (MOT) to increase its dividend or break itself into...
Published:
Biotech firm Biogen Idec (BIIB) has put itself on the block, another victim of shareholder activist by Carl Icahn. The company said that several firms had expressed interest. According to The Wall...
Published: